Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8685996 | 0.85 | KMT2A (0.69) | KMT2AIDO1MAOBKIF11BCHE | |
| SCHEMBL5314366 | 0.82 | IDO1 (0.51) | IDO1LMNAMAPTSMN1; SMN2MAOB | |
| SCHEMBL1170170 | 0.82 | KMT2A (0.51) | KMT2AIDO1MAOBKIF11BCHE | |
| SCHEMBL3124649 | 0.82 | IDO1 (0.41) | PTPN2PTPN1PTPN6IDO1LMNA | |
| SCHEMBL1109816 | 0.80 | CA2 (0.53) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2904642 | 0.79 | KMT2A (0.49) | KMT2APTPN2PTPN1PTPN6IDO1 | |
| SCHEMBL16682543 | 0.79 | CA2 (0.51) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1109812 | 0.79 | KMT2A (0.42) | KMT2AIDO1MEN1LMNASMN1; SMN2 | |
| SCHEMBL13737003 | 0.79 | ALDH1A1 (0.38) | KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL2076848 | 0.78 | TSHR (0.50) | LMNASMN1; SMN2MAOBAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-10-11 | — | — | US | disclosed |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-07-24 | — | — | US | disclosed |
| US-9597317-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-21 | — | — | US | disclosed |
| EP-2707359-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-9408850-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-08-09 | — | — | US | disclosed |
| CN-103534239-B | There is the indazole derivatives of the replacement of kinase inhibitory activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-20 | — | — | CN | disclosed |
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-20 | — | — | US | disclosed |
| EP-2707359-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-03-19 | — | — | EP | disclosed |
| CN-103534239-A | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2014-01-22 | — | — | CN | disclosed |
| WO-2012152763-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-15 | — | — | WO | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | KMT2A 1348/4885PTPN2 725/4885PTPN1 724/4885 |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | KMT2A 1116/4885PTPN2 633/4885PTPN1 645/4885 |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | KMT2A 1116/4885PTPN2 633/4885PTPN1 645/4885 |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | KMT2A 1116/4885PTPN2 633/4885PTPN1 645/4885 |
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | KMT2A 1116/4885PTPN2 633/4885PTPN1 645/4885 |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | KMT2A 1116/4885PTPN2 633/4885PTPN1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.